Our Firm is actively filing Xarelto lawsuits on behalf of individuals who are alleged to have experienced internal bleeding and other injuries related to its use.
New York, New York (PRWEB) December 23, 2014
Xarelto lawsuits (http://www.xareltolawsuit2015.com/) filed on behalf of individuals who allegedly suffered uncontrollable internal bleeding and other serious complications allegedly related to its use have begun to move forward in a federal multidistrict litigation underway in U.S. District Court, Eastern District of Louisiana, Bernstein Liebhard LLP reports. According to court documents, an Initial Case Management Order was issued on December 17th, which, among other things, directs the parties to submit written statements to the Court by January 20, 2015 outlining their preliminary understanding of the facts involved in the Xarelto litigation, a well as the critical factual and legal issues. (In Re: Xarelto Products Liability Litigation, No. 2592)
“Our Firm is actively filing Xarelto lawsuits on behalf of individuals who are alleged to have experienced internal bleeding and other injuries related to its use. We are pleased to see that the federal litigation is now moving ahead, and look forward to significant progress in the coming year,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free, no-obligation Xarelto case reviews to people who allegedly suffered serious injuries from the blood thinner, including uncontrollable bleeding, strokes, deep vein thrombosis or pulmonary embolism.
Xarelto (rivaroxaban) is a blood thinner that was approved by the U.S. Food & Drug Administration in 2011. The medication is currently indicated to prevent strokes in people with atrial fibrillation; as a treatment for deep vein thrombosis and pulmonary embolism; and to prevent deep vein thrombosis in patients undergoing hip or knee replacement surgery. *
According to court documents, the federal Xarelto litigation was established by the U.S. Judicial Panel on Multidistrict Litigation via a Transfer Order issued on December 12th. The Court’s Initial Case Management Order indicates that 21 Xarelto lawsuits were transferred to the proceeding, and that numerous additional filings are expected in the future. All of the claims pending in the Eastern District of Louisiana similarly allege, among other things, that the Xarelto’s manufacturers wrongfully marketed the medication as a superior alternative to warfarin, a blood thinner that has been in use for decades. The complaints point out that while there is currently no approved antidote to reverse Xarelto bleeding, hemorrhaging associated with warfarin can be stopped via the administration of Vitamin K.
Individuals who were allegedly harmed by Xarelto may be entitled to compensation for medical bills, lost wages, pain and suffering, and more. To learn more about filing a Xarelto lawsuit, please visit Bernstein Liebhard LLPs website, or call 800-511-5092 to schedule a free, no obligation case review.
*fda.gov/downloads/Drugs/DrugSafety/UCM280333.pdf, FDA, March 2014
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP